Discover how pembrolizumab, an immunotherapy drug, enhances disease-free survival in advanced soft tissue sarcoma, offering a ...
Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue sarcoma of the ...
Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue sarcoma of the ...
Lenvatinib plus pembrolizumab has improved survival rates for patients with intermediate-stage hepatocellular cancer, ...
PITTSBURGH — Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue ...
MedPage Today on MSN5d
Year in Review: Early Breast CancerNews in early breast cancer this year was marked by updated U.S. Preventive Services Task Force (USPSTF) screening ...
Patients with Advanced Solid Tumors who had Exhausted All Other Treatment Options and were PD-(L)1 Experienced Achieved Significant Tumor Volume Reductions and Prolonged Progression Free Survival ...
Citation: Clinical trial shows immunotherapy drug pembrolizumab improves outcomes for patients with soft tissue sarcoma (2024, November 12) retrieved 16 November 2024 from https://medicalxpress ...
Medpage Today on MSN4d
Perioperative Anti-PD-1 in Soft-Tissue Sarcoma Boosts Disease-Free SurvivalAdding a PD-1 inhibitor to standard of care improved disease-free survival (DFS) in stage III soft-tissue sarcoma of the ...
The combination of NUC-3373 plus pembrolizumab was generally well tolerated. Module 1 Selected Case Studies: NUC-3373 plus pembrolizumab in patients with advanced solid tumors 72-year-old patient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback